Crestwood Advisors Group LLC Purchases New Position in Profound Medical Corp. (NASDAQ:PROF)

Crestwood Advisors Group LLC purchased a new stake in Profound Medical Corp. (NASDAQ:PROFGet Rating) in the 2nd quarter, HoldingsChannel reports. The firm purchased 17,700 shares of the company’s stock, valued at approximately $129,000.

Several other institutional investors and hedge funds have also recently modified their holdings of PROF. Deerfield Management Company L.P. Series C boosted its holdings in Profound Medical by 32.1% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 1,713,797 shares of the company’s stock worth $19,246,000 after buying an additional 416,000 shares during the last quarter. Gagnon Securities LLC boosted its holdings in Profound Medical by 22.9% in the 1st quarter. Gagnon Securities LLC now owns 1,324,335 shares of the company’s stock worth $11,919,000 after buying an additional 246,978 shares during the last quarter. Letko Brosseau & Associates Inc. boosted its holdings in Profound Medical by 58.0% in the 1st quarter. Letko Brosseau & Associates Inc. now owns 1,299,125 shares of the company’s stock worth $11,701,000 after buying an additional 476,875 shares during the last quarter. Gagnon Advisors LLC boosted its holdings in Profound Medical by 9.7% in the 1st quarter. Gagnon Advisors LLC now owns 441,056 shares of the company’s stock worth $3,970,000 after buying an additional 38,879 shares during the last quarter. Finally, Royal Bank of Canada boosted its holdings in Profound Medical by 22.9% in the 1st quarter. Royal Bank of Canada now owns 321,701 shares of the company’s stock worth $2,896,000 after buying an additional 59,998 shares during the last quarter. Hedge funds and other institutional investors own 43.01% of the company’s stock.

Analyst Ratings Changes

Separately, Raymond James lowered their price objective on Profound Medical from $17.50 to $15.00 and set an “outperform” rating on the stock in a report on Monday, August 8th.

Profound Medical Price Performance

Shares of Profound Medical stock opened at $5.04 on Friday. The stock has a market cap of $105.08 million, a P/E ratio of -3.45 and a beta of 1.31. The stock’s 50 day simple moving average is $7.15 and its 200-day simple moving average is $7.81. Profound Medical Corp. has a 1-year low of $4.99 and a 1-year high of $16.23.

Profound Medical (NASDAQ:PROFGet Rating) last issued its earnings results on Thursday, August 4th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.14. The business had revenue of $2.03 million for the quarter, compared to analysts’ expectations of $1.90 million. Profound Medical had a negative return on equity of 38.97% and a negative net margin of 437.62%. As a group, research analysts expect that Profound Medical Corp. will post -1.27 EPS for the current fiscal year.

Profound Medical Profile

(Get Rating)

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland.

Read More

Want to see what other hedge funds are holding PROF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Profound Medical Corp. (NASDAQ:PROFGet Rating).

Institutional Ownership by Quarter for Profound Medical (NASDAQ:PROF)

Receive News & Ratings for Profound Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profound Medical and related companies with MarketBeat.com's FREE daily email newsletter.